Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Prostate Cancer Treatment and Research, Wnt/β-catenin signaling in development and cancer, PARP inhibition in cancer therapy, and Cancer Immunotherapy and Biomarkers.
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study
Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with <i>CCNE1</i> amplification or deleterious alterations in <i>FBXW7</i> or <i>PPP2R1A</i>
Abstract CT004: Intratumoral (IT) MEDI1191 + durvalumab (D): Update on the first-in-human study in advanced solid tumors
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <i>BRCA</i> Mutations among Patients with Advanced Solid Tumors
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Wnt/beta-catenin pathway: modulating anticancer immune response
Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer
Repurposing metformin for cancer treatment: current clinical studies
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application